Amylyx Pharmaceuticals, Inc. (AMLX) FinancialsAMLXAmylyx Pharmaceuticals, Inc.

Evaluating the bottom line, Amylyx Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -74.73%, provide a clear picture of how effectively AMLX converts its operational activities into shareholder value.

In the context of the broader market, AMLX competes directly with industry leaders such as XENE and IDYA. With a market capitalization of $3.53B, it holds a significant position in the sector. When comparing efficiency, AMLX's gross margin of N/A stands against XENE's N/A and IDYA's 100.00%. Such benchmarking helps identify whether Amylyx Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Amylyx has shown a significant turnaround with a 247% increase in stock price this year, driven by successful trial results for its drug avexitide, which reduced hypoglycemic events by 55%. However, the company continues to report substantial net losses, with a net income of -$43,423,000 in Q2 2026.